INTRODUCTION
A clinical application for gene therapeutics has been anticipated, but the delivery of genetic materials across cellular membranes has been a difficult challenge. Nucleic acids exhibit a short half-life because of their rapid degradation by circulating and intracellular nucleases. 1 In addition, rapid systemic clearance, low selectivity for the desired tissue, and poor cellular uptake limits their clinical application. 2, 3 Therefore, much effort has been devoted to the development of a delivery vehicle for the efficient delivery of nucleic acids, such as DNA and RNA, in vivo.
Liposome, in particular cationic liposome, is among the most commonly used non-viral vectors for gene delivery. 4 Cationic liposome, by virtue of a surface positive charge, forms complexes with the negatively charged nucleic acids, such as plasmid DNA (pDNA), through electrostatic interactions. 5 Such complexes (also called pDNA-lipoplexes) are thought to enter the cell through endocytosis or fusion with the plasma membrane, and they can also promote the release of pDNA from endosomal membranes following internalization. 6 However, unlike the noted success in in vitro application, in vivo application has been substantially restricted by a short blood circulation time. One approach to prolonging the blood circulation of lipoplex is by surface modification with the hydrophilic polymer polyethylene glycol (PEG). 7 PEG is thought to form a steric barrier around the lipoplex, which stifles clearance due to reduced plasma protein interaction and macrophage uptake, 7, 8 resulting in improved tissue distribution and higher transfection efficiencies in vivo. 9, 10 Nevertheless, although PEG is well known as a bio-inert and non-immunogenic polymer, we and other researchers have shown a high level of anti-PEG IgM production in blood following the systemic injection of PEG-coated nanocarriers. [11] [12] [13] [14] [15] This induced anti-PEG IgM production was found to bind to a subsequently injected dose of PEG-coated nanocarriers and trigger their rapid clearance from blood circulation via activation of the complement system. 13 A similar phenomenon was also observed after repeated injections of PEG-coated pDNA-lipoplexes 16 and pDNA encapsulated liposomes. 11 Due to a low in vivo transfection efficiency of non-viral vector, repeated administration is required in order to obtain the optimum therapeutic outcome. Hence, the anti-PEG IgM-mediated rapid clearance encountered upon repeated administration of PEG-coated liposomes may constitute a potential barrier against the efficacy and/or safety of gene delivery. However, the issue of how pDNA associated with the PEG-coated lipoplex contributes to an enhanced anti-PEG IgM production is yet to be fully elucidated.
We recently showed that CpG motifs in the pDNA sequence increase anti-PEG IgM production in response to PEG-coated pDNA-lipoplexes. 16 It is well known that CpG motifs in pDNA have a strong adjuvant effect through recognition by Toll-like receptors. 17 Furthermore, stimulation of the TLR signaling pathway in immune competent cells is known to activate the innate immune system with a subsequent induction of potent antibody responses. 16 Therefore, we assume that activation of innate immune systems by pDNA is a key factor for enhanced anti-PEG IgM production following injection with PEG-coated pDNAlipoplexes. To validate our assumption, we employed myeloid differentiation primary-response protein 88 (MyD88), which is essential for most TLR signaling (except for TLR3),mice and TLR9 knock out mice, and studied the effect of TLR signaling on enhanced anti-PEG IgM production following intravenous injections of PEG-coated pDNA-lipoplex (PDCL).
RESULTS

Effect of pDNA on anti-PEG IgM production
To show how pDNA associated with PEG-coated lipoplex affects anti-PEG IgM production, anti-PEG IgM production was assessed on day 5 after a single injection of either 'empty' PEG-coated cationic liposome (PCL) or PEG-coated pDNA-lipoplex (PDCL) (0.005-2.0 μmol phospholipids per mouse, 0.125-50 μg pDNA per mouse). As shown in Figure 1 , a single injection of PCL induced anti-PEG IgM production in a dose-dependent manner; increasing the phospholipid dose led to a significant decrease in the anti-PEG IgM production levels. To the contrary, a single injection of PDCL induced the production of substantial amounts of anti-PEG IgM regardless of the injected dose. These results were consistent with our earlier observation and suggested that the immunostimulatory effect of pDNA complexed with PCL increased anti-PEG IgM response at higher doses. 16 Since a two-fold increase in the anti-PEG IgM production level by PDCL was observed at a phospholipid dose of 0.5 μmol/mouse (corresponding to 12.5 μg pDNA per mouse) compared with PCL, a PDCL dose of 0.5 μmol per mouse (corresponding to 12.5 μg pDNA per mouse) was chosen for further experiments.
Effect of splenectomy on anti-PEG IgM production Our earlier study demonstrated that the spleen plays an important role in anti-PEG IgM production following intravenous injection of PEG-coated 'empty' neutral liposome. 19 The contribution of the spleen to anti-PEG IgM production following intravenous injection of either PCL or PDCL was also investigated. As shown in Figure 2 , anti-PEG IgM production in response to 'empty' PCL was almost non-existant in splenectomized mice, which was consistent with the results of our earlier study. 20 On the other hand, surprisingly, splenectomy did not attenuate the anti-PEG IgM production in splenectomized mice treated with PDCL. This result suggests that not only spleen but also other organs/tissues are involved in the production of anti-PEG IgM in response to PDCL.
Effect of MyD88 and TLR9 deficiency on anti-PEG IgM production The CpG motif in pDNA is well known to act as an activator of the innate immune system through TLR signaling, mainly TLR9, and/or other cytosolic DNA-sensing receptors. 17 To reveal the contribution of TLR activation to anti-PEG IgM production, the response to PDCL was determined in MyD88 knock out (KO) mice, 21 because MyD88 is essential for TLR signaling (TLR3 being an exception). 18 As shown in Figure 3 , compared with wild type mice, a two-fold decrease in the serum anti-PEG IgM level was observed in MyD88 KO mice following an injection of PDCL. On the other hand, comparable serum anti-PEG IgM levels were observed in both naïve and MyD88 KO mice following an injection of PCL. Then, to investigate the contribution of stimulation to the anti-PEG IgM production by pDNA via TLR9, PDCL was intravenously injected into both naïve and TLR9 KO mice. As shown in Figure 4 , compared with wild type mice, a significant reduction in the serum anti-PEG IgM level was observed in TLR9 KO mice (Po 0.01). Collectively, these results clearly emphasize the crucial role of MyD88/TLR9 signaling in the enhanced anti-PEG IgM production observed when PDCL is injected.
Cytokines secretion by injection of PDCL TLR-expressing cells extensively participate in the secretion of various cytokines, which in turn supports antibody production. 18 Therefore, the issue of whether PDCL could induce inflammatory cytokines via TLR9 activation was studied. Serum inflammatory cytokines (IL-6, TNF-α, IFN-γ and IFN-α) were determined at 4 h following the injection of either PCL or PDCL into wild type, MyD88 KO or TLR9 KO mice. As shown in Figure failed to induce the secretion of any inflammatory cytokines in wild type mice, PDCL caused remarkable secretion of all the inflammatory cytokines. Interestingly, no cytokines secretion was observed in either MyD88 KO or TLR9 KO mice treated with PDCL. These results clearly suggest that MyD88/TLR9 is predominantly involved in the activation of innate immunity following the injection of PDCL. In addition, these results indicate that residual bacterial lipopolysaccharide, 22 which is a representative TLR4 agonist, and/or other DNA sensing receptors, are not involved. These suggest that the massive innate immune response following injection of PDCL occurs dominantly through TLR9/ MyD88 signaling pathways.
DISCUSSION
Numerous studies have shown that repeated injection of exogenous DNAs, such as pDNA, oligodeoxynucleotide (ODN) or ribozyme, is required in order to gain long-term therapeutic efficacy. 23 In addition, to increase site-specific therapeutic efficacy, exogenous DNAs are conveyed to disease sites via drug delivery systems such as PEG-coated cationic liposome. However, we, 16 and others, 11 have found that a single injection of PEG-coated liposome can induce a robust amount of anti-PEG IgM production. Since anti-PEG IgM is well known to lead to a rapid blood clearance of sequential doses of PEG-coated nanocarrier and may induce complement activation, the issue of how PEG-coated nanocarriers activate the innate immune system should be elucidated.
Recently, we reported that, compared to CpG-free pDNA, complexation of pDNA containing CpG motifs with PEG-coated cationic liposomes further facilitated the induction of anti-PEG IgM production. 16 Since the CpG motif in pDNA is a representative TLR9 agonist, 18 it is easy to imagine that activation of TLR9 by the CpG motif in pDNA is responsible for the enhanced PEG-specific antibody response. However, Semple and colleagues 24 reported that injection of not only CpG containing ODN, but also CpG-free ODN-encapsulated PEG-coated liposomes induced rapid blood clearance of subsequent doses of PEG-coated liposomes via anti-PEG IgM production, although it has reported that some CpG-free ODNs have the ability to act as a TLR9 agonist. 25 To resolve these discrepancies, we studied the contribution of the activation of TLR9 by PEG-coated pDNA-lipoplex (PDCL) to the anti-PEG IgM response. Our results (Figures 3 and 4) revealed that the activation of TLR9 plays a critical role in the enhanced production of anti-PEG IgM following the injection of PDCL, and that TLR9 activation by the CpG motif is the causative factor for the enhanced anti-PEG IgM production following an injection of exogenous DNA containing PEG-coated lipoplex. We have observed a strong inverse relationship between the dose of initially injected PEGylated liposomes and the extent of the ABC phenomenon. 26 In the present study, we also observed that anti-PEG IgM production by PCL occurs in a dose-inverse dependent manner. However, PDCL induced the production of substantial amounts of anti-PEG IgM regardless of the injected lipid dose (Figure 1 ). It appears that such an inhibitory effect of the lipid dose on anti-PEG IgM production observed for PCL was completely diminished by the immunostimulatory effect of CpGcontaining pDNA complexed with PEG-coated cationic liposomes. These results clearly demonstrate that the complexation of stimulatory pDNA with PEG-coated cationic liposomes is sufficient to render the PEG-coated liposomes more immunogenic.
We previously demonstrated that the spleen plays a critical role in the induction of the production of anti-PEG IgM in response to PEG-coated liposomes. 19 We speculated that PEG-coated liposomes caused a T-cell-independent type 2 (TI-2) antibody response and marginal zone (MZ) B cells, which localize in the spleen and facilitate the recognition of TI-2 antigen, 27 as well as playing a major role in anti-PEG IgM production. Consistent with our previous study, 19 we showed that splenectomy remarkably attenuated the anti-PEG IgM response following the injection of PCL (Figure 2) . Surprisingly, splenectomy failed to attenuate the anti-PEG IgM response following the intravenous injection of PDCL ( Figure 2 ). These controversial results suggest that the anti-PEG IgM response against PDCL is mediated not only through the stimulation of splenic MZ B cells but also through the stimulation of B cells in blood circulation and/or other organs. It is well known that TLR9 is expressed not only in B cells but also in monocytes and virtually all dendritic cell (DC) subunits including conventional DCs, 28 and that they contribute B cell activation via the secretion of various types of cytokines following the activation of TLR9. 29 Herein, we speculate that the potent mitogen activity of the pDNA containing PEG-coated cationic liposomes might counteract the effect of splenectomy and the lack of MZ B cells via activation of the proliferation of a minor population of PEG-reactive B cells in blood circulation and/or in other organs. Interestingly, similar to the anti-PEG IgM response, a weak antibody response against TI-2 antigen was observed in CD19 deficient mice, which lack B-1 and MZ B cells but retains blood-circulating B cells. 30 In addition, blood circulating B cells reportedly produce the antibody response against (4-hydroxy-3-nitrophenyl)-acetyl conjugated ficoll, which is a representative TI-2 antigen, 31 when it was injected with TLR agonist. 32 It is well established that the stimulation of TLR9 by the CpG motif in pDNA plays a critical role in the activation of innate immunity through the production of inflammatory cytokines such as TNF-α, IL-6 and interferons (IFNs). 18, 28 These inflammatory cytokines are known to participate in the induction of IgM production, as discussed above. 29, 33 Accordingly, to gain insight onto the probable mechanism underlying the enhanced anti-PEG IgM response induced by PDCL, inflammatory cytokine production following intravenous injection of PDCL was investigated. Inflammatory cytokine secretion (IL-6, TNF-α, IFN-α and IFN-γ) was detected in wild type mice, but no cytokine secretion was detected in either MyD88 KO or TLR9 KO mice ( Figure 5 ). This indicates the crucial role of TLR signaling via TLR9 in the induction of cytokine secretion with the subsequent induction of anti-PEG IgM production against PEG in the PDCL. In recent reports, PEG modification of nanoparticles severely inhibited the endosomal escape of PEGylated nanoparticles following their endocytosis. 34 Because TLR9 is known to be expressed in endosomes, 17, 28 we assumed that the inhibition of endosomal escape of pDNAlipoplexes, as a result of PEG surface modification, would lead to efficient interaction between pDNA on the lipoplex surface and endosomal TLR9, and cause a substantial secretion of inflammatory cytokines. That development would trigger the robust production of anti-PEG IgM following an intravenous injection of PDCL.
The immune response against PEG is one of the key aspects and significantly limits the therapeutic application of many nucleic acid-containing PEGylated nanocarriers, including PEGylated lipoplexes. Many strategies have been adopted to reduce such immune responses against PEGylated nanocarriers. Judge and colleagues 11 reported that substituting a PEGylated lipid containing a C18 alkyl chain with that of a C14 alkyl chain induced a 3-fold decrease in the serum levels of anti-PEG IgM following the administration of stable plasmid lipid particles. In addition, our previous study showed that the absence of the CpG motif in pDNA could not induce an enhancement of anti-PEG IgM production, and results of the current study clearly showed why the presence of the CpG motif in pDNA enhances anti-PEG IgM production. We believe that avoiding TLR9 activation not only prevents the induction of cytokines secretion but also allows repeated systemic administration of PEG-coated gene delivery nanocarriers.
In the present study, we investigated how pDNA associated with the PDCL induces an enhancement of anti-PEG IgM production and showed that TLR9 signaling plays a key role in enhanced anti-PEG IgM production in a spleen-independent manner. Our study may have significant implications for the development of an efficient gene delivery system based on PEG-coated non-viral vectors. 
MATERIALS AND METHODS
Animals
Male BALB/c mice aged 4-5 weeks (20-25 g) were purchased from Japan SLC (Shizuoka, Japan). Male MyD88 knock out (KO) and TLR9 KO BALB/c mice 17,21 aged 4-7 weeks (20-25 g) were purchased from Oriental Bio Service (Kyoto, Japan). All mice were maintained under pathogen-free conditions. All animal experiments were evaluated and approved by the Animal and Ethics Review Committee of the University of Tokushima. pDNA pEGFP-N1 containing CpG motifs [4733 bp, 321 CpG points (13.56%)] was purchased from Clontech (CA, USA). pEGFP-N1 was amplified and purified as previously described. 16 
Preparation of cationic liposomes and PEGylation
Cationic liposomes, composed of DC-6-14:POPC = 1:1 (molar ratio), were prepared as previously described. 35 The mean diameters and zeta potentials of the resultant liposomes were 107.3 ± 3.8 nm and +26.3 ± 1.4 mV, respectively, as determined using a NICOMP 370 HPL submicron particle analyzer (Particle Sizing System, CA, USA). For PEGylation of the cationic liposomes, a post-insertion technique was used as previously described. 16 The mean diameter and zeta potential of PEGylated cationic liposomes (PCL) were 112.2 ± 4.8 nm and +15.7 ± 2.4 mV, respectively. The concentration of phospholipids was determined by colorimetric assay. 36 Preparation of PEG-coated pDNA-lipoplex Equal volumes of pDNA (12.5 μg) and PEG-coated cationic liposome (0.5 μmol phospholipids) were mixed and incubated for 20 min at room temperature. The mean diameter and zeta potential of the Immune stimulation by pDNA activates anti-PEG immunity Y Hashimoto et al resultant PEG-coated pDNA-lipoplex (PDCL) were 215.3 ± 28.6 nm and +14.5 ± 9.3 mV, respectively. No bands relating free pDNA were detected, indicating that virtually 100% of the pDNA was associated with PDCL.
Detection of serum anti-PEG IgM
At day 5 after intravenous injection of either PCL or PDCL (0.005-2.0 μmol phospholipids/mouse, 0.125-50 μg pDNA/mouse), at which point anti-PEG IgM production is markedly manifest, 16 the peripheral blood was withdrawn from each mouse. To obtain serum, the blood was placed at room temperature for 30 min and then centrifuged at 3000 rpm and 4°C for 15 min. The serum collected from naïve wild type mice was used as a control. A simple ELISA, as previously described, 16 was employed to detect anti-PEG IgM in the serum.
Effect of splenectomy on the anti-PEG IgM production Splenectomy was carried out according to a method described earlier. 19 For sham-operated mice, the skin and peritoneal membrane were surgically opened and closed. One day after surgery, either PCL or PDCL (0.5 μmol phospholipids/mouse, 12.5 μg pDNA/mouse) was injected into either splenectomized or sham-operated mice and blood samples were withdrawn on day 5 after injection. The detection of anti-PEG IgM in the sample was performed using ELISA as described above.
Measurement of cytokines
At 4 h after injection of either PCL or PDCL (0.5 μmol phospholipids/mouse, 12.5 μg pDNA/mouse) into wild type, MyD88 KO or TLR9 KO mice, the peripheral blood was withdrawn from each mouse. The serum was obtained as described above. The serum from naïve wild type mice served as a control. Interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interferon gamma (IFN-γ) in the serum were measured using a Quantikine Immunoassay Kit (R&D Systems, MN, USA). Interferon-α (IFN-α) in the serum was measured using a VeriKine Mouse Interferon Alpha ELISA Kit (PBL Biomedical, NJ, USA) according to the manufacturer's recommended instruction.
Statistical analysis
All values are expressed as the mean ± s.d. Statistical analysis was performed using a two-tailed unpaired Student's t-test and GraphPad InStat software (GraphPad Software, CA, USA). The level of significance was set at Po0.05.
